Group 1 - The core viewpoint of the article highlights the performance and holdings of the Agricultural Bank of China Healthcare Stock Fund, which has shown significant growth in recent months and years [1] - The fund's latest net value is 2.0003 yuan, reflecting a growth of 1.17% [1] - Over the past month, the fund has achieved a return of 4.93%, ranking 412 out of 1032 in its category [1] - In the last six months, the fund's return has been 50.76%, ranking 43 out of 993 [1] - Year-to-date, the fund has returned 46.69%, ranking 69 out of 983 [1] Group 2 - The top ten holdings of the Agricultural Bank of China Healthcare Stock Fund account for a total of 51.10%, with significant positions in companies such as Heng Rui Pharmaceutical (8.16%) and Zai Lab (7.99%) [1] - The fund was established on February 10, 2015, and as of June 30, 2025, it has a total size of 1.441 billion yuan [1] - The fund manager, Meng Yuan, has a master's degree and has held various positions in the financial industry, including roles at Bank of China Fund Management and Agricultural Bank of China Asset Management [1]

Group 1 - The core viewpoint of the articles is that Shanghai Bid Pharma Technology Co., Ltd. has undergone significant management changes in 2024, with a new management team focusing on internationalization and growth strategies [1][2][3] - The new management team is characterized by internal promotions and a younger demographic, with key members having long tenures at the company, ensuring familiarity with its culture and operations [2][3] - The company aims to enhance its global presence, having established regional centers in the US, India, and Germany, and is focusing on expanding its market share in Europe, India, and Japan [3][4] Group 2 - In 2024, Bid Pharma's overseas revenue reached 616 million yuan, accounting for 55.89% of total revenue, indicating a strong international market presence [3] - The company has implemented an equity incentive plan for 65 employees, with performance targets set for revenue and net profit growth of at least 10% in 2025 and 20% in 2026 [4] - The equity incentive plan is seen as a strategic tool to align the interests of key talents with the long-term development of the company, enhancing its governance structure [4]

注：赵芸女士在公司首次公开发行股票时任监事会主席，在股份限售方面有相关承诺。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 上海毕得医药科技股份有限公司（以下简称"公司"）董事会近日收到赵芸女士、张锐豪先生提交的书面 辞职报告。因公司内部工作调整，赵芸女士辞去公司董事及审计委员会委员、薪酬与考核委员会委员职 务，张锐豪先生辞去公司董事及战略委员会委员职务，辞任后，赵芸女士、张锐豪先生仍然担任公司其 他职务。公司于2025年8月8日召开职工代表大会，经全体与会职工代表表决，同意选举尚卓婷女士、许 丽姣女士担任公司第二届董事会职工代表董事。 一、董事离任情况 (一)提前离任的基本情况 ■ (二)离任对公司的影响 根据《公司法》《公司章程》及相关规定，赵芸女士、张锐豪先生辞职后不会导致公司董事会成员低于 法定最低人数，不会影响董事会依法规范运作，也不会影响公司正常的经营发展，张锐豪先生的辞职报 告自送达公司董事会之日起生效。根据《上海证券交易所科创板上市公司自律监管指引第1号一一规范 运作》相关规定，赵芸女士的辞任 ...

Core Viewpoint - The announcement details the resignation of two board members, Zhao Yun and Zhang Ruihao, and the election of two employee representative directors, Shang Zhuoting and Xu Lijiao, at Shanghai Bid Pharmaceutical Technology Co., Ltd. [2][4] Group 1: Board Resignation - Zhao Yun resigned from her positions as a director, audit committee member, and compensation and assessment committee member due to internal work adjustments, while Zhang Ruihao resigned as a director and strategic committee member [2][4] - Zhao Yun will continue to fulfill her duties until a new audit committee member is elected, as her resignation would otherwise leave the committee below the legal minimum [4] - Zhao Yun indirectly holds approximately 173,499 shares, accounting for about 0.1909% of the company's total equity, while Zhang Ruihao does not hold any shares [4] Group 2: Election of Employee Representative Directors - The company held a staff representative meeting on August 8, 2025, where Shang Zhuoting and Xu Lijiao were elected as employee representative directors [5] - The election results were publicly announced, and no objections were raised during the public notice period, making the results effective automatically [5] - The number of employee representative directors does not exceed half of the total board members, complying with relevant laws and regulations [5] Group 3: Background of Newly Elected Directors - Shang Zhuoting has a diverse background in sales and management, previously holding positions at various companies, including serving as the sales director for the China region at Shanghai Bluewood Chemical Co., Ltd. [8] - Xu Lijiao has experience in sales and management roles, including serving as the general manager of Shanghai Zhizhong Pharmaceutical Technology Co., Ltd. prior to her current position [10] - Both newly elected directors do not have any direct or indirect shareholdings that would conflict with their roles and meet the qualifications required by law [9][11]

Group 1 - The company announced that it will hold a staff representative meeting on August 8, 2025 [1] - During the meeting, the staff representatives voted to elect Ms. Shang Zhuoting and Ms. Xu Lijiao as representatives on the company's second board of directors [1]

Core Insights - The core viewpoint of the news is the performance and holdings of the Agricultural Bank of China Healthcare Stock Fund, which has shown significant growth in recent months and has a diversified portfolio in the healthcare sector [1]. Fund Performance - The latest net value of the Agricultural Bank of China Healthcare Stock Fund is 1.9772 yuan, reflecting a growth of 1.81% [1]. - The fund's return over the past month is 9.64%, ranking 129 out of 328 in its category [1]. - Over the last six months, the fund has achieved a return of 47.35%, ranking 12 out of 316 [1]. - Year-to-date, the fund has a return of 45.00%, ranking 18 out of 316 [1]. Fund Holdings - The top ten holdings of the Agricultural Bank of China Healthcare Stock Fund account for a total of 51.10% of the portfolio, with the following key positions: - Heng Rui Medicine: 8.16% - Zai Lab: 7.99% - Xin Li Tai: 5.84% - Rejig Bio: 5.63% - Kelun Pharmaceutical: 5.02% - HAO OBO: 4.36% - BeiGene: 3.61% - Yifang Bio: 3.58% - Aosaikang: 3.52% - Bid Pharma: 3.39% [1]. Fund Background - The Agricultural Bank of China Healthcare Stock Fund was established on February 10, 2015, and as of June 30, 2025, it has a total scale of 1.441 billion yuan [1]. - The fund manager is Meng Yuan, who has a master's degree and has held various positions in the fund management industry, including roles at Bank of China Fund Management and Agricultural Bank of China Asset Management [1].

证券代码：688073 证券简称：毕得医药 公告编号：2025-070 上海毕得医药科技股份有限公司 关于公司董事辞职暨选举职工董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 上海毕得医药科技股份有限公司（以下简称"公司"）董事会近日收到赵芸 女士、张锐豪先生提交的书面辞职报告。因公司内部工作调整，赵芸女士辞去公 司董事及审计委员会委员、薪酬与考核委员会委员职务，张锐豪先生辞去公司董 事及战略委员会委员职务，辞任后，赵芸女士、张锐豪先生仍然担任公司其他职 务。公司于 2025 年 8 月 8 日召开职工代表大会，经全体与会职工代表表决，同 意选举尚卓婷女士、许丽姣女士担任公司第二届董事会职工代表董事。 一、董事离任情况 根据《公司法》《上海证券交易所科创板股票上市规则》等法律法规以及《公 司章程》的相关规定，公司于 2025 年 8 月 8 日召开职工代表大会，经与会代表 认真审议并投票表决，同意选取尚卓婷女士、许丽姣女士为公司第二届董事会职 工代表董事。公司对选举结果进行了公示，2025 年 8 ...

Core Insights - The core viewpoint of the news is the performance and holdings of the Agricultural Bank of China Healthcare Stock Fund, which has shown significant growth in recent months and has a diversified portfolio in the healthcare sector [1]. Fund Performance - The latest net value of the Agricultural Bank of China Healthcare Stock Fund is 1.9462 yuan, reflecting a growth of 2.54% [1]. - The fund's return over the past month is 11.14%, ranking 101 out of 333 in its category [1]. - Over the last six months, the fund has achieved a return of 46.50%, ranking 10 out of 327 [1]. - Year-to-date, the fund has returned 42.73%, ranking 18 out of 327 [1]. Fund Holdings - The top ten holdings of the Agricultural Bank of China Healthcare Stock Fund account for a total of 51.10% of the portfolio, with the following key positions: - Heng Rui Medicine: 8.16% - Zai Lab: 7.99% - Xin Li Tai: 5.84% - Hotgen Biotech: 5.63% - Kelun Pharmaceutical: 5.02% - HAOYOBIO: 4.36% - BeiGene: 3.61% - Eucure Biopharma: 3.58% - Aosaikang: 3.52% - Bide Pharmaceutical: 3.39% [1]. Fund Background - The Agricultural Bank of China Healthcare Stock Fund was established on February 10, 2015, and as of June 30, 2025, it has a total scale of 1.441 billion yuan [1]. - The fund manager is Meng Yuan, who has a master's degree and has held various positions in the financial industry, including roles at Bank of China Fund Management and Agricultural Bank of China Asset Management [1].

Core Points - The Shanghai Composite Index closed at 3638.40 points with a change of 0.12% and a total trading volume of 1,206.179 billion yuan [1] - Eight A-shares experienced a crossover where the 5-day moving average fell below the 10-day moving average, indicating potential bearish trends [1] Group 1: Stock Performance - Stock "信立泰" (Code: 002294) decreased by 1.86% with a 5-day moving average of 49.37 yuan and a 10-day moving average of 49.62 yuan, showing a distance of -0.49% [1] - Stock "万邦德" (Code: 002082) decreased by 1.36% with a 5-day moving average of 7.48 yuan and a 10-day moving average of 7.52 yuan, also showing a distance of -0.49% [1] - Stock "毕得医药" (Code: 688073) decreased by 2.96% with a 5-day moving average of 59.09 yuan and a 10-day moving average of 59.27 yuan, indicating a distance of -0.30% [1] Group 2: Additional Stocks with Moving Average Crossovers - Stock "吉贝尔" (Code: 688566) decreased by 3.58% with a 5-day moving average of 33.90 yuan and a 10-day moving average of 33.97 yuan, showing a distance of -0.20% [1] - Stock "诺诚健华" (Code: 688428) decreased by 6.03% with a 5-day moving average of 30.02 yuan and a 10-day moving average of 30.07 yuan, indicating a distance of -0.18% [1] - Stock "丽人丽妆" (Code: 605136) increased by 0.81% with a 5-day moving average of 9.82 yuan and a 10-day moving average of 9.84 yuan, showing a distance of -0.15% [1]

Core Viewpoint - The A-share market is experiencing a slight decline, with the Shanghai Composite Index down by 0.28% and a total trading volume of 878.86 billion yuan as of 10:30 AM [1] Group 1: Market Performance - The Shanghai Composite Index is at 3623.70 points, reflecting a decrease of 0.28% [1] - The total trading volume in the A-share market is reported at 878.86 billion yuan [1] Group 2: Moving Averages Analysis - Seven A-shares have seen their 5-day moving averages cross below their 10-day moving averages, indicating potential bearish trends [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Xintai (002294) with a distance of -0.51% - Wanbangde (002082) with a distance of -0.45% - Haixiang Pharmaceutical (002099) with a distance of -0.24% [1] Group 3: Individual Stock Performance - Xintai (002294) is down by 2.07% with a latest price of 47.79 yuan, which is 3.66% below its 10-day moving average [1] - Wanbangde (002082) has decreased by 0.95%, trading at 7.30 yuan, 2.93% below its 10-day moving average [1] - Haixiang Pharmaceutical (002099) is down by 0.33%, with a latest price of 6.08 yuan, 1.95% below its 10-day moving average [1] - Other stocks such as Bidai Pharmaceutical (688073) and Kewah (002335) also show declines in their respective prices and moving averages [1]